Operator
Good morning, ladies and gentlemen, and welcome to the Exelixis First Quarter 2021 Financial Results Conference Call. My name is Daphne, and I ll be your operator for today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please proceed.
Susan T. Hubbard
Executive Vice President, Public Affairs and Investor Relations
Thank you, Daphne, and thank you all for joining us for the Exelixis First Quarter 2021 Financial Results Conference Call. Joining me on today s call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; P.J. Haley, our Executive Vice President of Commercial; and Gisela Schwab, our Chief Medical Officer, who together will review our corporate, financial, commercial and development progress for the first quarter 2021 ended March 31, 2021. Peter Lamb, our Chief S
Operator
Greetings, and welcome to the Global Blood Therapeutics conference call. [Operator instructions] I would now like to turn the call over to Steven Immergut. Please, go ahead.
Steven Immergut
Senior Vice President, Head of Corporate Communications and Investor Relations
Thank you, and welcome to GBT s conference call to discuss the Company s financial results for the first quarter of 2021 and to provide a business update. I m Steven Immergut, head of communications and investor relations. Joining me on the call are Dr. Ted Love, our president and CEO, who will provide an update on our progress in the first quarter; Jeff Farrow, our chief financial officer, who will review our financial results; David Johnson, or DJ, our chief commercial officer, will give an update on the Oxbryta launch. Ted will then introduce Dr.